Related Experiment Video
Updated: May 23, 2026

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay
Published on: May 12, 2023
Severe haematological complications during treatment with natalizumab
L Midaglia1, M Rodriguez Ruiz, D Muñoz-García
1Neurology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain. lulimidaglia@gmail.com
Abstract:
The safety profile of natalizumab has been widely discussed due to several cases of progressive multifocal leukoencephalopathy, reported worldwide. Since the launch of natalizumab, 32 patients have been treated at our centre. In this context, we describe two cases (6.25%), one of immune-mediated acute haemolytic anaemia (IAHA) and another of immune thrombocytopenic purpura during treatment with natalizumab. The temporal relationship between drug administration and the nature of the haematological complications, confirmed with the serological findings in the case of the IAHA, suggests that natalizumab is the most probable cause for these adverse events. Although very uncommon, the haematological complications are severe enough to justify a close and careful monitoring for all patients with multiple sclerosis treated with an immunosuppressant treatment.
Related Concept Videos
Hemodialysis II: Procedure and Complications
Hypersensitivity Reactions: Cytolytic Reactions
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Rh Blood Group
Drug toxicity: Idiosyncratic Reactions
